midazolam sun 1 mg/ml
sun pharmaceutical industries europe b.v. - tarile de jos - midazolamum - sol. inj./perf. in seringa preumpluta - 1mg/ml - hipnotice si sedative benzodiazepine si derivati
midazolam sun 2 mg/ml
sun pharmaceutical industries europe b.v. - tarile de jos - midazolamum - sol. inj./perf. in seringa preumpluta - 2mg/ml - hipnotice si sedative benzodiazepine si derivati
foster nexthaler 200 micrograme/6 micrograme
chiesi farmaceutici s.p.a. - italia - combinatii (beclometasonum+formoterolum) - pulb. de inhal. - 200micrograme/6micrograme - adrenergice inhalante adrenergice si alte med. pt. trat. bolilor obstructive c.r
foster nexthaler 200 micrograme/12 micrograme
chiesi farmaceutici s.p.a. - italia - combinatii (beclometasonum+formoterolum) - pulb. de inhal. - 200micrograme/12micrograme - adrenergice inhalante adrenergice si alte med. pt. trat. bolilor obstructive c.r
clexane solutie injectabila in seringa preumpluta 2000 ui (20 mg)/0,2 ml
sanofi romania srl - enoxaparini de sodiu - solutie injectabila in seringa preumpluta - 2000 ui (20 mg)/0,2 ml
clexane solutie injectabila in seringa preumpluta 4000 ui (40 mg)/0,4 ml
sanofi romania srl - enoxaparini de sodiu - solutie injectabila in seringa preumpluta - 4000 ui (40 mg)/0,4 ml
clexane solutie injectabila in seringa preumpluta 8000 ui (80 mg)/0,8 ml
sanofi romania srl - enoxaparini de sodiu - solutie injectabila in seringa preumpluta - 8000 ui (80 mg)/0,8 ml
kabiven
fresenius kabi ab - suedia - combinatii - emulsie perf. - solutii pentru administrare intravenoasa solutii pentru nutritie parenterala
kabiven peripheral
fresenius kabi ab - suedia - combinatii - emulsie perf. - solutii pentru administrare intravenoasa solutii pentru nutritie parenterala
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agenți antineoplazici - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.